OncoLens, an innovative leader in the oncology space, is thrilled to announce a successful funding round of $16 million aimed at expanding its AI-driven oncology care platform. This significant financial boost reflects the growing recognition of OncoLens' commitment to revolutionizing cancer care through enhanced multidisciplinary collaboration, comprehensive analytics, and advanced clinical decision support tools. The platform's unique capability to seamlessly integrate patient data from various sources鈥攊ncluding Electronic Medical Records (EMRs), genomic databases, Digital Imaging and Communications in Medicine (PACS), and pathology reports鈥攑ositions OncoLens at the forefront of effective cancer treatment management. By harnessing both structured and unstructured data, the OncoLens platform empowers healthcare providers to extract actionable insights, ensuring the identification of patients eligible for clinical trials, biomarker testing, stem cell therapies, and more. This new funding will bolster the company's efforts in refining these capabilities and enhancing the user experience for multi-disciplinary care teams both within and across healthcare enterprises. As we look to the future, OncoLens is excited to push the boundaries of oncology care, making it more connected, efficient, and patient-centric. For those interested in a firsthand experience of our platform, we invite you to connect with us at info@oncolens.com for a demo. Together, we can transform the treatment landscape for cancer patients everywhere.
OncoLens Secures $16M in Series B Funding for AI-Driven Oncology Care Platform
Recently funded 路 $16.0M Series bHealthcare
Get the full OncoLens company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
